Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EX103 in Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT06021678Phase 2Recruiting
- Sponsor
- ExcelMab
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EX103 in non-Hodgkin lymphoma (NHL), sponsored by ExcelMab. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Incidence and Severity of Adverse Events at 3.5 years. Started Nov 2021; status: recruiting.
02
Drugs
EX103
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06021678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021678.